中国多中心研究探索奥雷巴替尼治疗慢性期CML的优化剂量

亿欧网2025-05-16

一项多中心回顾性研究通过倾向性评分匹配（PSM）比较了奥雷巴替尼40mg隔日一次（QOD）和30mg QOD起始剂量在慢性髓性白血病（CML）患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂（TKI）耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2535538289?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-16 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535538289","market":"us","top_or_hot":-1,"title":"中国多中心研究探索奥雷巴替尼治疗慢性期CML的优化剂量","media":"亿欧网","content":"<div>\n<p>一项多中心回顾性研究通过倾向性评分匹配（PSM）比较了奥雷巴替尼40mg隔日一次（QOD）和30mg QOD起始剂量在慢性髓性白血病（CML）患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂（TKI）耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例...</p>\n\n<a href=\"https://ky.jrj.com.cn/2025/05/16100850435864.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国多中心研究探索奥雷巴替尼治疗慢性期CML的优化剂量</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国多中心研究探索奥雷巴替尼治疗慢性期CML的优化剂量\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-16 10:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://ky.jrj.com.cn/2025/05/16100850435864.shtml><strong>亿欧网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一项多中心回顾性研究通过倾向性评分匹配（PSM）比较了奥雷巴替尼40mg隔日一次（QOD）和30mg QOD起始剂量在慢性髓性白血病（CML）患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂（TKI）耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例...</p>\n\n<a href=\"https://ky.jrj.com.cn/2025/05/16100850435864.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4195","symbol_name":"互助储蓄与抵押信贷金融服务","start_time":0,"source_url":"https://ky.jrj.com.cn/2025/05/16100850435864.shtml","article_id":"2535538289","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535538289","pubTimestamp":1747361330,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"一项多中心回顾性研究通过倾向性评分匹配比较了奥雷巴替尼40mg隔日一次和30mg QOD起始剂量在慢性髓性白血病患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例。经过PSM调整后，两组基线协变量相似。相比之下，40mg QOD组在这些指标上的表现略低。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4195":"互助储蓄与抵押信贷金融服务","PSM":"Principal U.S. Small Cap Index ETF","OS":"OneStream, Inc.","BK4077":"互动媒体与服务","BK4211":"区域性银行","PFS":"Provident Financial Services Inc","CHR":"悦享控股","BK4097":"系统软件"},"translate_title":"Multicenter study in China to explore the optimal dose of oribatinib in chronic phase CML","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSM":1,"CHR":1,"PFS":1,"OS":1},"content_text":"一项多中心回顾性研究通过倾向性评分匹配（PSM）比较了奥雷巴替尼40mg隔日一次（QOD）和30mg QOD起始剂量在慢性髓性白血病（CML）患者中的安全性和疗效。研究发现，30mg QOD起始剂量不仅更安全、耐受性更好，而且在疗效上与40mg QOD相当。研究共纳入282例对其他酪氨酸激酶抑制剂（TKI）耐药或不耐受的成人CML慢性期患者，其中30mg QOD组66例，40mg QOD组216例。经过PSM调整后，两组基线协变量相似。结果显示，30mg QOD组在3个月内达到完全血液学反应（CHR）、主要细胞遗传学反应（MCyR）、完全细胞遗传学反应（CCyR）、主要分子学反应（MMR）和MR4的比例分别为94%、75%、67%、44%和28%，6年累计发生率分别为84%、84%、57%和36%，6年无进展生存率（PFS）和总生存率（OS）分别为78%和82%。相比之下，40mg QOD组在这些指标上的表现略低。该研究由北京大学人民医院江倩教授、上海交通大学医学院附属瑞金医院周励教授和河南省肿瘤医院张䶮莉教授领导，并发表于《Haematologica》。\n\n\r\n            责任编辑：栎树","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535538289","isCrawlerRequest":true}